Broadest consideration of socio-economic factors when setting prices for a first-line broad spectrum antibiotic across multiple priority countries*

GSK
GSK considers the most socio-economic factors when setting prices for a first-line broad-spectrum antibiotic and targets almost 90% of priority countries relevant for this product. This is comparatively broad as the industry considers only two socio-economic factors and targets only 33% of relevant priority countries, on average.
Continue reading

Consideration of four socio-economic factors to set prices for essential HIV/AIDS product in multiple priority countries

Johnson & Johnson
Johnson & Johnson uses four socio-economic factors to set prices for essential HIV/AIDS products and targets 100% of priority countries relevant for this product. This is comparatively broad as the industry considers only two socio-economic factors and targets only 33% of relevant priority countries, on average.
Continue reading

Considering multiple local needs to facilitate rational use of products

Novartis
Novartis adapts brochures and packaging in multiple ways to facilitate rational use of products.
Continue reading

Publishing the registration status of products, country-by-country

Gilead
Gilead publishes where it has filed for specific products to be registered, and when filings were successful.
Continue reading

BAAF Distribution Optimisation project

Novo Nordisk
Novo Nordisk is working with distributors across different countries in Africa to optimise the supply chain and reduce the price to patients of its full diabetes portfolio.
Continue reading

Broad consideration of socio-economic factors when setting prices for a first-line heart disease medicine in multiple priority countries*

AstraZeneca
AstraZeneca considers five socio-economic factors when setting prices for a first-line heart disease medicine and targets 27% of priority countries. This is comparatively broad as the industry considers only two socio-economic factors per strategy, on average.
Continue reading

New pricing policy based on an analysis of populations’ ability to pay in key out-of-pocket markets

AstraZeneca
AstraZeneca has a new pricing policy for its respiratory and cardiovascular disease products in certain key out-of-pocket markets in scope, based on an ability-to-pay analysis.
Continue reading